Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS)

Circulation

Volumn 102, Issue 1, 2000, Pages 42-47

  Festa, Andreas ^a,d   D'Agostino Jr , Ralph ^b   Howard, George ^b   Mykkänen, Leena ^a   Tracy, Russell P ^c   Haffner, Steven M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atherosclerosis; Inflammation; Insulin; Insulin resistance syndrome; Proteins

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INSULIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SYNDROME DELINEATION; SYSTOLIC BLOOD PRESSURE;

EID: 0034604248     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.1.42     Document Type: Article

References (44)

1. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol. 1982;27:83-111.
2. Hatanaka K, Li XA, Masuda K, et al. Immunohistochemical localization of C-reactive protein binding sites in human aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995;45:635-641.
3. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
4. Cermak J, Key N, Bach R, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82: 513-520.
5. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
6. Haverkate F, Thompson SG, Pyke SDM, et al, for the European Concerted Action on Thrombosis and Disabilities Angina Pectons Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
7. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
8. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 1999;99:237-242.
9. Mendall MA, Patel P, Ballam L, et al. C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
10. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of c-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176.
11. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40: 1286-1292.
12. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 1999;19:972-978.
13. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993;13:1865-1873.
14. Després JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996; 334:952-957.
15. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997;5:294-315.
16. Wagenknecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design and recruitment results. Ann Epidemiol. 1995;5:464-471.
17. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985. Technical report series No. 727.
18. Herbert V, Lau K, Gottlieb C, et al. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965;25:1375-1384.
19. Sobey WJ, Beer SF, Carrington CA, et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulin. Biochem J. 1989;260:535-541.
20. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrinol Rev. 1985;6:45-86.
21. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986;23:113-122.
22. Welch S, Gebhart SSP, Bergman RN, et al. Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 1990;71:1508-1518.
23. Steil GM, Volund A, Kahn SE, et al. Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes. 1993: 42:250-256.
24. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem. 1997;43:52-58.
25. Geffken D, Keating F, Kennedy M, et al. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med. 1994;118:1106-1109.
26. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19: 562-568.
27. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
28. Mohamed-Ali V, Gould MM, Gillies S, et al. Association of proinsulin-like molecules with lipids and fibrinogen in nondiabetic subjects: evidence against a modulating role for insulin. Diabetologia. 1995; 38:1110-1116.
29. Haffner SM, D'Agostino R Jr, Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. Diabetes. 1996;45:742-748.
30. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241-1248.
31. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med. 1993;36:611-622.
32. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97:2000-2002.
33. Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068-1076.
34. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol. 1992;12:1789-1797.
35. De Feo P, Volpi E, Lucidi P, et al. Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes. 1993;42:995-1002.
36. Gordon AH, Koj A. The Acute Phase Response to Injury and Infection. Amsterdam, Netherlands: Elsevier; 1985:10. Research Monographs in Cell and Tissue Physiology.
37. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265-271.
38. Grimble RF. Nutrition and cytokine action. Nutr Res Rev. 1990;3: 193-210.
39. Wolbink GJ. CRP-mediated activation of complement in vivo. J Immunol. 1996;157:473-479.
40. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1995;156:4815-4820.
41. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human c-reactive protein in health and disease. J Clin Invest. 1993;90:1351-1357.
42. Eriksson K-F, Lindgarde F. Prevention of type-2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia. 1991;34: 891-898.
43. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet. 1994;344:1383-1389.
44. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial: HOT Study Group. Lancet. 1998;351:1755-1762.